Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2017

Dec 13, 2017

29977_dirs_2017-12-13_f2736ed4-3096-4050-87f7-8bb817bda3c9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-12-12

Reporting Person: Terifay Robert J (EVP Commercial)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-12-12 Non-Qualified Stock Option (right to buy) $378.98 A 32300 Acquired 2027-12-12 Common Stock (32300) Direct

Footnotes

F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.